An open-label, uncontrolled, dose-escalation, phase 1 trial to investigate the tolerability and safety of OPB-171775 in patients with advanced or metastatic malignant solid tumors
Latest Information Update: 11 Oct 2024
Price :
$35 *
At a glance
- Drugs OPB-171775 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Mar 2021 New trial record